Relevance of biomarkers across different neurodegenerative diseases

Alexander J Ehrenberg^{1

2

3}, Ayesha Khatun⁴, Emma Coomans⁵, Matthew J Betts^{6

7}, Federica Capraro^{8

9}, Elisabeth H Thijssen^{10

11}, Konstantin Senkevich^{12

13}, Tehmina Bharucha¹⁴, Mehrsa Jafarpour¹⁵, Peter N E Young^{16

17}, William Jagust^{18

19}, Stephen F Carter^{20

21}, Tammaryn Lashley^{15

22}, Lea T Grinberg^{10

23

24}, Joana B Pereira^{25

26}, Niklas Mattsson-Carlgren^{16

17}, Nicholas J Ashton^{16

17

27

28}, Jörg Hanrieder^{15

16}, Henrik Zetterberg^{15

16

29

30}, Michael Schöll^{15

16

26}, Ross W Paterson⁴

Affiliations

¹ Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. alexander.ehrenberg@ucsf.edu.
² Department of Integrative Biology, University of California, Berkeley, Berkeley, CA, USA. alexander.ehrenberg@ucsf.edu.
³ Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA. alexander.ehrenberg@ucsf.edu.
⁴ Dementia Research Centre, University College London Institute of Neurology, London, UK.
⁵ Department of Radiology & Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam Neuroscience, Amsterdam, The Netherlands.
⁶ German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
⁷ Institute of Cognitive Neurology and Dementia Research, Otto von Guericke University Magdeburg, Magdeburg, Germany.
⁸ The Francis Crick Institute, London, UK.
⁹ Department of Neuromuscular Diseases, University College London Queen Square Institute of Neurology, London, UK.
¹⁰ Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
¹¹ Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands.
¹² Petersburg Nuclear Physics Institute names by B.P. Konstantinov of National Research Center, Kurchatov Institute, St. Petersburg, Russia.
¹³ First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia.
¹⁴ Oxford Glycobiology Institute, Department of Biochemistry , University of Oxford, Oxford, UK.
¹⁵ Department of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
¹⁶ Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
¹⁷ Wallenberg Center for Molecular and Translational Medicine, Lund University, Lund, Sweden.
¹⁸ Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA.
¹⁹ Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
²⁰ Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
²¹ Wolfson Molecular Imaging Centre, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
²² Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.
²³ University of São Paulo Medical School, São Paulo, Brazil.
²⁴ Global Brain Health Institute, San Francisco, CA, USA.
²⁵ Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
²⁶ Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
²⁷ King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
²⁸ NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.
²⁹ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
³⁰ UK Dementia Research Institute at University College London, London, UK.

PMID: 32404143
PMCID: PMC7222479
DOI: 10.1186/s13195-020-00601-w

Review

Relevance of biomarkers across different neurodegenerative diseases

Alexander J Ehrenberg et al. Alzheimers Res Ther. 2020.

. 2020 May 13;12(1):56.

doi: 10.1186/s13195-020-00601-w.

Authors

Affiliations

¹ Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. alexander.ehrenberg@ucsf.edu.
² Department of Integrative Biology, University of California, Berkeley, Berkeley, CA, USA. alexander.ehrenberg@ucsf.edu.
³ Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA. alexander.ehrenberg@ucsf.edu.
⁴ Dementia Research Centre, University College London Institute of Neurology, London, UK.
⁵ Department of Radiology & Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam Neuroscience, Amsterdam, The Netherlands.
⁶ German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
⁷ Institute of Cognitive Neurology and Dementia Research, Otto von Guericke University Magdeburg, Magdeburg, Germany.
⁸ The Francis Crick Institute, London, UK.
⁹ Department of Neuromuscular Diseases, University College London Queen Square Institute of Neurology, London, UK.
¹⁰ Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
¹¹ Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands.
¹² Petersburg Nuclear Physics Institute names by B.P. Konstantinov of National Research Center, Kurchatov Institute, St. Petersburg, Russia.
¹³ First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia.
¹⁴ Oxford Glycobiology Institute, Department of Biochemistry , University of Oxford, Oxford, UK.
¹⁵ Department of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
¹⁶ Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
¹⁷ Wallenberg Center for Molecular and Translational Medicine, Lund University, Lund, Sweden.
¹⁸ Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA.
¹⁹ Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
²⁰ Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
²¹ Wolfson Molecular Imaging Centre, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
²² Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.
²³ University of São Paulo Medical School, São Paulo, Brazil.
²⁴ Global Brain Health Institute, San Francisco, CA, USA.
²⁵ Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
²⁶ Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
²⁷ King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
²⁸ NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.
²⁹ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
³⁰ UK Dementia Research Institute at University College London, London, UK.

PMID: 32404143
PMCID: PMC7222479
DOI: 10.1186/s13195-020-00601-w

Erratum in

Correction to: Relevance of biomarkers across different neurodegenerative diseases.
Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH, Senkevich K, Bharucha T, Jafarpour M, Young PNE, Jagust W, Carter SF, Lashley T, Grinberg LT, Pereira JB, Mattsson-Carlgren N, Ashton NJ, Hanrieder J, Zetterberg H, Schöll M, Paterson RW. Ehrenberg AJ, et al. Alzheimers Res Ther. 2020 Jun 9;12(1):71. doi: 10.1186/s13195-020-00637-y. Alzheimers Res Ther. 2020. PMID: 32517788 Free PMC article.

Abstract

Background: The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use, appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For example, neuropathological investigations of Alzheimer's disease pathogenesis can fall in disagreement with conclusions reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field.

Purpose of review: Along with separate review articles covering fluid and imaging biomarkers in this issue of Alzheimer's Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease research, commenting on appropriate use, interpretation, and considerations for implementation across different neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel modalities that have been proposed in the landscape of neurodegenerative disease research and care.

Keywords: Alzheimer’s disease; Amyloid; Biomarkers; Cerebrospinal fluid; Magnetic resonance imaging; Neurodegenerative diseases; Neurofilament light chain; Plasma biomarkers; Positron emission tomography; Tau.

PubMed Disclaimer

Conflict of interest statement

AJE has accepted compensation as a consultant to Epiodyne Inc. WJJ is a consultant for Genentech, Novartis, and Bioclinica. NM serves as a consultant for the Alzheimer’s Disease Neuroimaging Initiative. LTG has received research support from AVID Radiopharmecuticals and Eli Lily. HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Alzecure and Biogen; and is a co-founder of the Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. MS has served at a scientific advisory board for Servier. All other authors declare that they have no competing interests.

References

1. Jack CR, Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562. doi: 10.1016/j.jalz.2018.02.018. - DOI - PMC - PubMed
1. Nicoll JAR, Buckland GR, Harrison CH, Page A, Harris S, Love S, et al. Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer’s disease. Brain. 2019;142(7):2113–2126. doi: 10.1093/brain/awz142. - DOI - PMC - PubMed
1. Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–2193. doi: 10.1093/brain/awy146. - DOI - PMC - PubMed
1. Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement. 2019;15(1):1–7. doi: 10.1016/j.jalz.2018.07.216. - DOI - PMC - PubMed
1. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123(1):1–11. doi: 10.1007/s00401-011-0910-3. - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Relevance of biomarkers across different neurodegenerative diseases

Affiliations

Relevance of biomarkers across different neurodegenerative diseases

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials